Developer docs
API playgroundTry for free, no card

Search company profiles

Evox Therapeutics

Full company profile

uuid0000i8q

Namestring
Evox Therapeutics
Legal namestring
Evox Therapeutics Limited
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Evox Therapeutics is a privately held, preclinical-stage biotechnology company founded in 2016 as a spinout from the University of Oxford and the Karolinska Institute, headquartered at the Oxford Science Park in Oxford, United Kingdom. The company is developing a proprietary exosome-based delivery platform — branded ExoEdit® — that pairs engineered extracellular vesicles (exosomes) with CRISPR-based gene editing tools to enable safe, redosable, non-viral delivery of genetic medicines into the central nervous system, an area where lipid nanoparticles are largely liver-tropic and adeno-associated viral vectors face immunogenicity, limited cargo capacity, and persistence risks. Supporting technologies include the DeliverEx™ drug-loading platform (using proprietary scaffold proteins TSPAN2 and TSPAN3 that deliver 5–10-fold improvement in cargo loading), Fc-binding extracellular vesicles (Fc-EVs) for antibody-directed tissue targeting, and the engEx-AAV™ technology acquired from Codiak Biosciences in 2023 for AAV-in-exosome delivery.

Evox's wholly owned preclinical pipeline targets genetically validated mechanisms in severe neurodegenerative diseases: MSH3 for Huntington's disease (lead program), ATXN2 for amyotrophic lateral sclerosis and spinocerebellar ataxia type 2, and MECP2 for Rett syndrome (added via a February 2026 collaboration with the Rett Syndrome Research Trust). The company is also exploring cardiovascular applications through an August 2023 research collaboration with the Icahn School of Medicine at Mount Sinai. The intellectual property portfolio covers more than 100 granted patents globally, including US Patent US11,640,272 covering exosome purification methods and four additional manufacturing patents issued in 2022.

Evox is pre-revenue with no commercial products. Its business model is built around retaining worldwide rights to its proprietary programs while pursuing strategic pharmaceutical licensing and co-development partnerships, disease-focused non-profit collaborations (RSRT), and academic research alliances to advance the pipeline toward an IND filing and first-in-human studies targeted for 2027. The company is backed by a syndicate of life-sciences-focused investors including Oxford Science Enterprises, Redmile Group, OrbiMed, GV (Google Ventures), Invus, and Eli Lilly, and has raised approximately $169M in cumulative disclosed equity and grant financing across multiple rounds between 2016 and 2026.

Short descriptiontext

Evox Therapeutics is a preclinical Oxford-based biotechnology company developing exosome-based CRISPR gene editing therapies, led by its ExoEdit® platform, for severe neurodegenerative diseases including Huntington's, ALS, SCA2, and Rett syndrome.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
exosome therapeutics, gene editing delivery, neurodegenerative disease therapy, CNS drug delivery, extracellular vesicle platform
Industry3 codes
PRIMARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Exosome-based Gene Therapy
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Development & Licensing
TypeLicensing Royalties
Description

As a pre-clinical stage biotech company, Evox currently has no revenue. The company is developing a proprietary pipeline of exosome-based gene editing therapies for rare neurodegenerative diseases. Future revenue is expected to derive from licensing deals, co-development agreements, and ultimately commercialization of its therapeutic candidates upon regulatory approval.

evoxtherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1ExoEdit
Description

Proprietary genome-editing technology platform that harnesses the natural delivery power of exosomes to precisely deliver CRISPR-based editing tools into specific organs and cells.

evoxtherapeutics.com
Core offering1 text field

Evox Therapeutics develops and engineers exosome-based (extracellular vesicle) delivery vehicles for genetic medicines, pairing proprietary CRISPR-based gene editors with engineered exosomes to safely and potently deliver gene editing therapies to the central nervous system. The company's lead therapeutic candidates target genetically validated disease drivers in Huntington's disease (MSH3), ALS and SCA2 (ATXN2), and Rett syndrome (MECP2), with clinical entry planned for 2027.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 10X gene editing efficiency compared to leading non-viral platforms in mouse models
+4 more records
Product overview1 text field

Evox Therapeutics is a biotechnology company developing a unified platform of exosome-based gene editing therapies. The company's core technology is the ExoEdit® platform, which pairs the natural transport capabilities of exosomes with proprietary CRISPR-based editors to enable safe, redosable delivery of genetic medicines to the central nervous system. Supporting technologies include the DeliverEX drug loading platform for efficient cargo loading and Fc-EV targeting technology for tissue-specific delivery. The proprietary pipeline includes therapeutic programs targeting MSH3 for Huntington's disease, ATXN2 for ALS and SCA2, and MECP2 for Rett syndrome, all at preclinical stage with clinical entry planned for 2027.

Product and service5 records
1ExoEdit® Genome Editing Platform
CategoryCore technology platform
Description

Proprietary genome-editing technology that harnesses the natural delivery capabilities of exosomes to precisely deliver CRISPR-based editing tools into specific organs and cells, including the central nervous system. Designed to enable safer, more effective, and redosable genetic medicines than LNP or viral vector approaches.

2Huntington's Disease Program (MSH3)
CategoryTherapeutic candidate
Description

Preclinical gene editing therapeutic candidate designed to address the root genetic cause of Huntington's disease by targeting the MSH3 gene to stabilize CAG repeat expansions, with the goal of halting disease progression in approximately 70,000 patients across the U.S. and Western Europe.

3ALS Program (ATXN2)
CategoryTherapeutic candidate
Description

Preclinical gene editing therapeutic candidate designed to address ALS by targeting the ATXN2 gene to prevent TDP-43 protein pathology, which underlies 97% of ALS cases, with the goal of stopping disease progression and preserving remaining motor neuron function.

4SCA2 Program (ATXN2)
CategoryTherapeutic candidate
Description

Preclinical gene editing therapeutic candidate targeting ATXN2 gene expansions to halt or reverse disease progression in Spinocerebellar Ataxia Type 2 (SCA2), a rare autosomal dominant neurodegenerative disorder typically manifesting in mid-adulthood, with no cure and only symptomatic management available.

5Rett Syndrome Program (MECP2)
CategoryTherapeutic candidate
Description

Preclinical gene editing therapeutic candidate using the ExoEdit® platform to restore functional MECP2 expression in the central nervous system, addressing the root genetic cause of Rett syndrome caused by pathogenic loss-of-function variants in the X-linked MECP2 gene. Developed in partnership with the Rett Syndrome Research Trust.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Evox partnered with RSRT to assess whether its ExoEdit® exosome-based delivery platform can enable gene editing treatments for Rett syndrome, a severe neurodevelopmental disorder caused by MECP2 gene mutations. The collaboration aims to address the key challenge of safely delivering gene editing therapies to the CNS. Successful findings could establish a preclinical program targeting the majority of Rett syndrome patients. RSRT awarded $1.8 million specifically for non-viral delivery approaches including Evox's engineered exosome technology, and RSRT's $40M Roadmap to Cures initiative (2024) funds this collaboration.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-08-04
Description

Evox entered a research collaboration and option agreement with Icahn Mount Sinai to develop exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology for improving treatments for heart disease. The collaboration combines Evox's exosome technology with Mount Sinai's deep understanding of gene delivery and cardiovascular research. The exoAAV technology has demonstrated ability to improve in vivo delivery to cardiomyocytes even in the presence of high levels of neutralizing anti-AAV antibodies.

3Codiak Biosciences
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-06-20
Description

Evox acquired Codiak Biosciences' engEx-AAV™ technology platform, including all intellectual property rights and exclusive access to certain engineering and manufacturing rights. This technology enables active loading of AAV into exosomes followed by release upon delivery into recipient cells, improving AAV delivery, increasing expression breadth in preclinical models, and shielding AAVs from neutralizing antibodies. This acquisition further strengthens Evox's dominant intellectual property portfolio.

evoxtherapeutics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Evox was founded in 2016 as a spinout from Oxford University, with roots firmly grounded in Oxford University and the Karolinska Institute. The company leverages a world-leading academic and collaborative ecosystem. Key scientific co-founders include Prof. Matthew Wood of University of Oxford who pioneered exosome therapeutics by bioengineering exosomes for RNA delivery in the brain.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Evox was founded in 2016 as a spinout from the Karolinska Institute. Co-founder Prof. Samir El Andaloussi leads the exosome research group at Karolinska Institutet's Department of Laboratory Medicine. He is a pioneer in extracellular vesicle-based drug delivery, having characterised exosome biology and engineered novel exosome platforms for macromolecule-based therapies targeting neurodegenerative and neuromuscular diseases.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Codiak BioSciences
TypeDirect peer
Description

Was the leading independent exosome therapeutics company before winding down; Evox acquired its engEx-AAV platform in 2023, making Codiak the most directly comparable prior peer in engineered exosome therapeutics for gene delivery.

TypeDirect peer
Description

Clinical-stage biotech developing exosome-based therapeutics (dermaseptin/StealthX platform) for inflammatory and rare diseases; the only other listed exosome-therapeutics peer with human clinical experience and a directly analogous delivery-platform thesis.

TypeBroad incumbent
Description

Leading commercial-stage CRISPR/Cas9 gene editing company (Casgevy approved); Evox's ExoEdit platform is an exosome-enabled CRISPR delivery system, and CRISPR Therapeutics' Douglas Treco sits on Evox's board, signaling direct technical overlap.

TypeBroad incumbent
Description

Clinical-stage in vivo CRISPR/Cas9 leader using LNP delivery; directly comparable as the leading non-viral CRISPR delivery competitor to Evox's exosome approach, with programs in transthyretin amyloidosis and HAE.

TypeBroad incumbent
Description

Clinical-stage CRISPR gene editing company with both in vivo (LNP) and ex vivo (ex vivo edited HSC) programs; comparable as a competitor in CNS-relevant editing (e.g., LCA10 retinal program) targeting similar patient populations to Evox's rare disease pipeline.

TypeBroad incumbent
Description

Clinical-stage base editing company with LNP-based in vivo delivery; comparable as a next-generation editing platform competitor targeting similar CNS, liver and rare disease indications with non-viral delivery.

TypeBroad incumbent
Description

Commercial-stage gene therapy company (Hemgenix approved) with CNS AAV programs including Huntington's disease (AMT-130); the most direct AAV-based CNS competitor to Evox's MSH3 program in Huntington's.

TypeBroad incumbent
Description

Clinical-stage biotech focused on neurodegeneration with proprietary delivery platforms (e.g., enzyme transport vehicle/OTV) to cross the blood-brain barrier; comparable as a BBB-penetrating CNS therapeutic delivery competitor.

TypeBroad incumbent
Description

Clinical-stage AAV gene therapy company with CNS programs including Huntington's disease and ALS SOD1; comparable as a leading AAV-based CNS gene therapy competitor with established platform partnerships (e.g., Pfizer, Novartis).

TypeEmerging player
Description

Clinical-stage AAV gene therapy company with CNS pipeline including APOE4 Alzheimer's and Friedreich's ataxia; comparable as an emerging CNS-focused gene therapy peer pursuing overlapping CNS indications with novel delivery approaches.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Evox Therapeutics

Exosome-based Gene Therapyevoxtherapeutics.com

Evox Therapeutics is a preclinical Oxford-based biotechnology company developing exosome-based CRISPR gene editing therapies, led by its ExoEdit® platform, for severe neurodegenerative diseases including Huntington's, ALS, SCA2, and Rett syndrome.

What Evox Therapeutics does

Evox Therapeutics is a privately held, preclinical-stage biotechnology company founded in 2016 as a spinout from the University of Oxford and the Karolinska Institute, headquartered at the Oxford Science Park in Oxford, United Kingdom. The company is developing a proprietary exosome-based delivery platform — branded ExoEdit® — that pairs engineered extracellular vesicles (exosomes) with CRISPR-based gene editing tools to enable safe, redosable, non-viral delivery of genetic medicines into the central nervous system, an area where lipid nanoparticles are largely liver-tropic and adeno-associated viral vectors face immunogenicity, limited cargo capacity, and persistence risks. Supporting technologies include the DeliverEx™ drug-loading platform (using proprietary scaffold proteins TSPAN2 and TSPAN3 that deliver 5–10-fold improvement in cargo loading), Fc-binding extracellular vesicles (Fc-EVs) for antibody-directed tissue targeting, and the engEx-AAV™ technology acquired from Codiak Biosciences in 2023 for AAV-in-exosome delivery.

Evox's wholly owned preclinical pipeline targets genetically validated mechanisms in severe neurodegenerative diseases: MSH3 for Huntington's disease (lead program), ATXN2 for amyotrophic lateral sclerosis and spinocerebellar ataxia type 2, and MECP2 for Rett syndrome (added via a February 2026 collaboration with the Rett Syndrome Research Trust). The company is also exploring cardiovascular applications through an August 2023 research collaboration with the Icahn School of Medicine at Mount Sinai. The intellectual property portfolio covers more than 100 granted patents globally, including US Patent US11,640,272 covering exosome purification methods and four additional manufacturing patents issued in 2022.

Evox is pre-revenue with no commercial products. Its business model is built around retaining worldwide rights to its proprietary programs while pursuing strategic pharmaceutical licensing and co-development partnerships, disease-focused non-profit collaborations (RSRT), and academic research alliances to advance the pipeline toward an IND filing and first-in-human studies targeted for 2027. The company is backed by a syndicate of life-sciences-focused investors including Oxford Science Enterprises, Redmile Group, OrbiMed, GV (Google Ventures), Invus, and Eli Lilly, and has raised approximately $169M in cumulative disclosed equity and grant financing across multiple rounds between 2016 and 2026.

Evox Therapeutics firmographics

Firmographics
Name
Evox Therapeutics
Legal name
Evox Therapeutics Limited
Website
https://evoxtherapeutics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Evox Therapeutics is a preclinical Oxford-based biotechnology company developing exosome-based CRISPR gene editing therapies, led by its ExoEdit® platform, for severe neurodegenerative diseases including Huntington's, ALS, SCA2, and Rett syndrome.
Ownership category
akta.pro rank

Evox Therapeutics industry classification

Industry
Product category
Exosome-based Gene Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Exosome therapeutics
  • Gene editing delivery
  • Neurodegenerative disease therapy
  • CNS drug delivery
  • Extracellular vesicle platform

Where Evox Therapeutics is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Evox Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Biopharmaceutical Development & Licensing: As a pre-clinical stage biotech company, Evox currently has no revenue. The company is developing a proprietary pipeline of exosome-based gene editing therapies for rare neurodegenerative diseases. Future revenue is expected to derive from licensing deals, co-development agreements, and ultimately commercialization of its therapeutic candidates upon regulatory approval.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Evox Therapeutics product offering

Product offering

Core offering

Evox Therapeutics develops and engineers exosome-based (extracellular vesicle) delivery vehicles for genetic medicines, pairing proprietary CRISPR-based gene editors with engineered exosomes to safely and potently deliver gene editing therapies to the central nervous system. The company's lead therapeutic candidates target genetically validated disease drivers in Huntington's disease (MSH3), ALS and SCA2 (ATXN2), and Rett syndrome (MECP2), with clinical entry planned for 2027.

Product overview

Evox Therapeutics is a biotechnology company developing a unified platform of exosome-based gene editing therapies. The company's core technology is the ExoEdit® platform, which pairs the natural transport capabilities of exosomes with proprietary CRISPR-based editors to enable safe, redosable delivery of genetic medicines to the central nervous system. Supporting technologies include the DeliverEX drug loading platform for efficient cargo loading and Fc-EV targeting technology for tissue-specific delivery. The proprietary pipeline includes therapeutic programs targeting MSH3 for Huntington's disease, ATXN2 for ALS and SCA2, and MECP2 for Rett syndrome, all at preclinical stage with clinical entry planned for 2027.

Differentiator

Problem solved

Functional benefit

Brands

  • ExoEdit: Proprietary genome-editing technology platform that harnesses the natural delivery power of exosomes to precisely deliver CRISPR-based editing tools into specific organs and cells.

Products and services

  • ExoEdit® Genome Editing Platform Proprietary genome-editing technology that harnesses the natural delivery capabilities of exosomes to precisely deliver CRISPR-based editing tools into specific organs and cells, including the central nervous system. Designed to enable safer, more effective, and redosable genetic medicines than LNP or viral vector approaches.
  • Huntington's Disease Program (MSH3) Preclinical gene editing therapeutic candidate designed to address the root genetic cause of Huntington's disease by targeting the MSH3 gene to stabilize CAG repeat expansions, with the goal of halting disease progression in approximately 70,000 patients across the U.S. and Western Europe.
  • ALS Program (ATXN2) Preclinical gene editing therapeutic candidate designed to address ALS by targeting the ATXN2 gene to prevent TDP-43 protein pathology, which underlies 97% of ALS cases, with the goal of stopping disease progression and preserving remaining motor neuron function.
  • SCA2 Program (ATXN2) Preclinical gene editing therapeutic candidate targeting ATXN2 gene expansions to halt or reverse disease progression in Spinocerebellar Ataxia Type 2 (SCA2), a rare autosomal dominant neurodegenerative disorder typically manifesting in mid-adulthood, with no cure and only symptomatic management available.
  • Rett Syndrome Program (MECP2) Preclinical gene editing therapeutic candidate using the ExoEdit® platform to restore functional MECP2 expression in the central nervous system, addressing the root genetic cause of Rett syndrome caused by pathogenic loss-of-function variants in the X-linked MECP2 gene. Developed in partnership with the Rett Syndrome Research Trust.

Quantifiable outcome

  • 10X gene editing efficiency compared to leading non-viral platforms in mouse models
  • +4 more outcomes

Companies that use Evox Therapeutics

Customer profile

Segments4 records

Ideal customer profiles2 records

Evox Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Evox Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and strategic.

  • Rett Syndrome Research Trust (RSRT)coreStrategic or Co-development Partner · 26 February 2026Evox partnered with RSRT to assess whether its ExoEdit® exosome-based delivery platform can enable gene editing treatments for Rett syndrome, a severe neurodevelopmental disorder caused by MECP2 gene mutations. The collaboration aims to address the key challenge of safely delivering gene editing therapies to the CNS. Successful findings could establish a preclinical program targeting the majority of Rett syndrome patients. RSRT awarded $1.8 million specifically for non-viral delivery approaches including Evox's engineered exosome technology, and RSRT's $40M Roadmap to Cures initiative (2024) funds this collaboration.
  • Icahn School of Medicine at Mount SinaistrategicStrategic or Co-development Partner · 4 August 2023Evox entered a research collaboration and option agreement with Icahn Mount Sinai to develop exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology for improving treatments for heart disease. The collaboration combines Evox's exosome technology with Mount Sinai's deep understanding of gene delivery and cardiovascular research. The exoAAV technology has demonstrated ability to improve in vivo delivery to cardiomyocytes even in the presence of high levels of neutralizing anti-AAV antibodies.
  • Codiak BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 20 June 2023Evox acquired Codiak Biosciences' engEx-AAV™ technology platform, including all intellectual property rights and exclusive access to certain engineering and manufacturing rights. This technology enables active loading of AAV into exosomes followed by release upon delivery into recipient cells, improving AAV delivery, increasing expression breadth in preclinical models, and shielding AAVs from neutralizing antibodies. This acquisition further strengthens Evox's dominant intellectual property portfolio.
  • Oxford University / Oxford University InnovationcoreStrategic or Co-development Partner · 1 January 2016Evox was founded in 2016 as a spinout from Oxford University, with roots firmly grounded in Oxford University and the Karolinska Institute. The company leverages a world-leading academic and collaborative ecosystem. Key scientific co-founders include Prof. Matthew Wood of University of Oxford who pioneered exosome therapeutics by bioengineering exosomes for RNA delivery in the brain.
  • Karolinska InstitutetcoreStrategic or Co-development Partner · 1 January 2016Evox was founded in 2016 as a spinout from the Karolinska Institute. Co-founder Prof. Samir El Andaloussi leads the exosome research group at Karolinska Institutet's Department of Laboratory Medicine. He is a pioneer in extracellular vesicle-based drug delivery, having characterised exosome biology and engineered novel exosome platforms for macromolecule-based therapies targeting neurodegenerative and neuromuscular diseases.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Evox Therapeutics competitors and assessment

Company assessment

Direct peers

  • Codiak BioSciences: Was the leading independent exosome therapeutics company before winding down; Evox acquired its engEx-AAV platform in 2023, making Codiak the most directly comparable prior peer in engineered exosome therapeutics for gene delivery.
  • Capricor Therapeutics: Clinical-stage biotech developing exosome-based therapeutics (dermaseptin/StealthX platform) for inflammatory and rare diseases; the only other listed exosome-therapeutics peer with human clinical experience and a directly analogous delivery-platform thesis.

Broad incumbents

  • CRISPR Therapeutics: Leading commercial-stage CRISPR/Cas9 gene editing company (Casgevy approved); Evox's ExoEdit platform is an exosome-enabled CRISPR delivery system, and CRISPR Therapeutics' Douglas Treco sits on Evox's board, signaling direct technical overlap.
  • Intellia Therapeutics: Clinical-stage in vivo CRISPR/Cas9 leader using LNP delivery; directly comparable as the leading non-viral CRISPR delivery competitor to Evox's exosome approach, with programs in transthyretin amyloidosis and HAE.
  • Editas Medicine: Clinical-stage CRISPR gene editing company with both in vivo (LNP) and ex vivo (ex vivo edited HSC) programs; comparable as a competitor in CNS-relevant editing (e.g., LCA10 retinal program) targeting similar patient populations to Evox's rare disease pipeline.
  • Beam Therapeutics: Clinical-stage base editing company with LNP-based in vivo delivery; comparable as a next-generation editing platform competitor targeting similar CNS, liver and rare disease indications with non-viral delivery.
  • uniQure: Commercial-stage gene therapy company (Hemgenix approved) with CNS AAV programs including Huntington's disease (AMT-130); the most direct AAV-based CNS competitor to Evox's MSH3 program in Huntington's.
  • Denali Therapeutics: Clinical-stage biotech focused on neurodegeneration with proprietary delivery platforms (e.g., enzyme transport vehicle/OTV) to cross the blood-brain barrier; comparable as a BBB-penetrating CNS therapeutic delivery competitor.
  • Voyager Therapeutics: Clinical-stage AAV gene therapy company with CNS programs including Huntington's disease and ALS SOD1; comparable as a leading AAV-based CNS gene therapy competitor with established platform partnerships (e.g., Pfizer, Novartis).

Emerging players

  • Lexeo Therapeutics: Clinical-stage AAV gene therapy company with CNS pipeline including APOE4 Alzheimer's and Friedreich's ataxia; comparable as an emerging CNS-focused gene therapy peer pursuing overlapping CNS indications with novel delivery approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Evox Therapeutics social profiles

Digital presence

Evox Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Evox Therapeutics leadership team

Management profile

Number of profiles

Profiles12 records

Evox Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Evox Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evox Therapeutics

What does Evox Therapeutics do?

Evox Therapeutics develops and engineers exosome-based (extracellular vesicle) delivery vehicles for genetic medicines, pairing proprietary CRISPR-based gene editors with engineered exosomes to safely and potently deliver gene editing therapies to the central nervous system. The company's lead therapeutic candidates target genetically validated disease drivers in Huntington's disease (MSH3), ALS and SCA2 (ATXN2), and Rett syndrome (MECP2), with clinical entry planned for 2027.

Is Evox Therapeutics a public or private company?

Evox Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Evox Therapeutics founded?

Evox Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Evox Therapeutics based?

Evox Therapeutics is headquartered in Oxford, United Kingdom, in the Europe region.

How does Evox Therapeutics make money?

One revenue line is on record: biopharmaceutical Development & Licensing.

Who are Evox Therapeutics's main competitors?

Direct peers on record are Codiak BioSciences and Capricor Therapeutics. Broad incumbents are CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, Beam Therapeutics, uniQure, Denali Therapeutics and Voyager Therapeutics. Lexeo Therapeutics is listed as an emerging player.

Does Evox Therapeutics have an API?

No public API is recorded for Evox Therapeutics.

What industry is Evox Therapeutics in?

Evox Therapeutics's product category is Exosome-based Gene Therapy. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsExtracellular Vesicle Product Developer Creates Potency AssayEvox Therapeutics developed a potency assay for its extracellular vesicle product, which measures dose-response on a cell line. The assay is pre-qualified and transferred to QC, with full qualification planned for a first-in-human study next year. The company hopes to adapt it for multiple products in its pipeline.American Banking and Market NewsEvox Therapeutics (NASDAQ:EVOXW) Stock Price Down 20% – Time to Sell?Evox Therapeutics shares fell 20% during mid-day trading on Tuesday, trading as low as $0.24. Approximately 49,535 shares were traded, a 55% increase from the average daily volume of 31,983. The company's stock closed at $0.30.FinanzNachrichten.deBis zu 2,1 Milliarden US-Dollar: Was die Exosomen-Deals von Eli Lilly und Takeda heute für NurExone bedeutenEli Lilly and Takeda announced exosome deals with Evox Therapeutics totaling about $2.08 billion in milestone payments. The deals, announced in 2020, were not immediate payments but success-dependent milestones. NurExone Biologic uses a similar exosome platform for its ExoPTEN candidate.European BiotechnologyInside exosomes: Nature’s drug carriersExosomes are being developed as drug carriers to overcome delivery hurdles, with companies like Evox Therapeutics and Aruna Bio advancing CNS and stroke therapies. Evox targets Huntington's disease with a Phase 1/2 trial planned for 2027, while Aruna Bio's AB126 reached Phase 1b. The field is expected to see IP consolidation and manufacturability breakthroughs over the next 5–10 years.Labiotech.euHow Evox Therapeutics is targeting CNS diseases with exosomesEvox Therapeutics uses engineered exosomes to deliver genetic medicines into the brain, targeting Huntington's disease and ALS. The company is extending its platform from RNA and biologics into gene editing, aiming for commercially scalable treatments. The discussion covers delivery, pipeline, and potential patient impact in ten years.TalkMarketsExosome Therapeutics Market Size, Trends, and Strategic Outlook 2026-2033The global exosome therapeutics market is projected to grow from USD 299.4 million in 2025 to USD 1,961.1 million by 2032, driven by advancements in targeted drug delivery and increased R&D investments. Key developments include regulatory fast-tracking in South Korea, technological breakthroughs in the U.S., and strategic partnerships among industry players like Evox Therapeutics and ExoCoBio. However, supply chain disruptions for lipid nanoparticle components due to geopolitical tensions in Eastern Europe have introduced cost pressures and production delays.GlobeNewswireGlobal Exosome-Based Therapy Market Size to Hit USD 288.10 Million by 2035 – SNS InsiderThe SNS Insider market research report projects the global exosome-based therapy market to grow from USD 54.08 million in 2025 to USD 288.10 million by 2035, representing a compound annual growth rate of 18.22%, driven by increasing clinical research and demand for cell-free regenerative therapies. The oncology segment held 38% market share in 2025, while North America commanded 44% of the global market, with Asia-Pacific emerging as the fastest-growing region at approximately 23.31% CAGR. Codiak BioSciences and Evox Therapeutics reported clinical and preclinical advances in March and February 2025 respectively, highlighting progress in engineered exosome platforms for cancer immunotherapy and neurodegenerative disease applications.PharmiWeb.comEvox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit® Technology to Enable Gene Editing in Rett SyndromeEvox Therapeutics announced a collaboration with the Rett Syndrome Research Trust to assess whether its ExoEdit® exosome-based delivery platform can enable gene editing treatments for Rett syndrome, a severe neurodevelopmental disorder caused by mutations in the MECP2 gene. The partnership aims to address the key challenge of safely delivering gene editing therapies to the central nervous system, with successful findings potentially establishing a preclinical program targeting the majority of Rett syndrome patients. This collaboration represents an expansion of exosome-based therapeutic applications into neurological diseases where current non-viral delivery methods have failed to reach the brain.ReverserettRett Cures: Non-Viral DeliveryThe Rett Syndrome Research Trust awarded $1.8 million in funding to advance non-viral delivery methods for genetic medicines targeting Rett syndrome, addressing key limitations of viral vectors such as inability to re-dose and cargo capacity constraints. The trust is supporting multiple parallel approaches including engineered exosomes through Oxford-based biotech Evox Therapeutics, lipid nanoparticles through Jennifer Doudna's lab at UC Berkeley, and ribonucleoprotein complexes through Yale and MIT researchers. These non-viral delivery methods offer advantages including repeat dosing capability and more effective diffusion throughout the brain compared to traditional AAV-based approaches.SeedtableExplore 69 Best Pharma Startups to watch in 2025. Discover innovative companies, funding insights, and industry trends.The article presents a curated list of six pharmaceutical and biotechnology startups to watch in 2025, highlighting their funding status and core technologies. Featured companies include Indee Labs, HistoSonics, Prokarium, Evox Therapeutics, and Roquette, covering areas such as CAR-T manufacturing, histotripsy, and synthetic biology vaccines.